

## **Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB**

**Lund, Sweden, November 13, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX)**, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on May 5, 2020 has been appointed.

Pursuant to the instruction for the Nomination Committee adopted by the AGM on May 9, 2019, the Nomination Committee for the Alligator Bioscience AGM 2020 shall consist of four members, representing the three largest shareholders at the last weekday of June, together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.

Based on the above, the Nomination Committee for the AGM 2020 has been established to consist of the following persons, together representing approximately 20 per cent of the shares and votes in the company as per the end of October 2019:

- Hans-Peter Ostler, representing Jonas Sjögren;
- Jan Lundström, representing Sunstone Life Science Ventures II K/S;
- Lars Bergkvist, representing Lars Spånberg; and
- Peter Benson, Chairman of the Board.

Lars Bergkvist has been appointed Chairman of the Nomination Committee.

The task of the Nomination Committee's prior to AGM is to prepare and submit proposals regarding the Chairman of the AGM, the number of Board members elected by the AGM, the Chairman and other Board members elected by the AGM, the fees and other remuneration for each of the Board members elected by the AGM and for members of Board committees, the number of auditors, the auditors, the fee for auditors and election of a Nomination Committee, or alternatively a decision on principles for appointing a Nomination Committee, as well as instructions for the Nomination Committee.

Shareholders wishing to submit comments proposals to the Nomination Committee may do so via email to [info@alligatorbioscience.com](mailto:info@alligatorbioscience.com) marked "Att. Nomination committee" or by letter to Alligator Bioscience AB, Nomination Committee, Medicon Village, 223 81 Lund, Sweden. To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than 31 January 2020.

The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website.

**For further information:**

Cecilia Hofvander, Director Investor Relations & Communications

Phone +46 46 540 82 06

E-mail: [cecilia.hofvander@alligatorbioscience.com](mailto:cecilia.hofvander@alligatorbioscience.com).

*The information was submitted for publication, through the agency of the contact person set out above, at 10:30 a.m. CET on November 13, 2019.*

**About Alligator Bioscience**

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes six lead clinical and preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit [www.alligatorbioscience.com](http://www.alligatorbioscience.com).